MX2019005459A - Tratamiento de infarto de miocardio con lipoproteinas de alta densidad reconstituidas. - Google Patents
Tratamiento de infarto de miocardio con lipoproteinas de alta densidad reconstituidas.Info
- Publication number
- MX2019005459A MX2019005459A MX2019005459A MX2019005459A MX2019005459A MX 2019005459 A MX2019005459 A MX 2019005459A MX 2019005459 A MX2019005459 A MX 2019005459A MX 2019005459 A MX2019005459 A MX 2019005459A MX 2019005459 A MX2019005459 A MX 2019005459A
- Authority
- MX
- Mexico
- Prior art keywords
- myocardial infarction
- treatment
- high density
- density lipoprotein
- reconstituted high
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662420050P | 2016-11-10 | 2016-11-10 | |
| US201762472240P | 2017-03-16 | 2017-03-16 | |
| PCT/AU2017/051232 WO2018085890A1 (en) | 2016-11-10 | 2017-11-10 | Reconstituted high density lipoprotein treatment of myocardial infarction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019005459A true MX2019005459A (es) | 2019-08-12 |
Family
ID=62109053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005459A MX2019005459A (es) | 2016-11-10 | 2017-11-10 | Tratamiento de infarto de miocardio con lipoproteinas de alta densidad reconstituidas. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200038481A1 (https=) |
| EP (1) | EP3538105A4 (https=) |
| JP (2) | JP2019533705A (https=) |
| KR (2) | KR20190084095A (https=) |
| CN (2) | CN116196395A (https=) |
| AU (2) | AU2017358402B2 (https=) |
| BR (1) | BR112019007709A2 (https=) |
| CA (1) | CA3043110A1 (https=) |
| IL (1) | IL266428B2 (https=) |
| MX (1) | MX2019005459A (https=) |
| SG (2) | SG11201903945XA (https=) |
| WO (1) | WO2018085890A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6937313B2 (ja) | 2015-11-09 | 2021-09-22 | リヴァンプ メディカル リミテッド | 心血管処置のための血流低減器 |
| CN113195038B (zh) * | 2018-12-11 | 2025-12-30 | 瑞普医药有限公司 | 用于调节体腔中的血流量的系统、装置以及方法 |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| WO2025210584A1 (en) * | 2024-04-04 | 2025-10-09 | CSL Innovation Pty Ltd | Reconstituted high density lipoprotein treatment of myocardial infarction |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003239489A1 (en) * | 2002-05-17 | 2003-12-02 | Esperion Therapeutics, Inc. | Method of treating dyslipidemic disorders |
| MX2012014928A (es) * | 2010-06-30 | 2013-03-22 | Csl Ltd | Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. |
| PL2793913T3 (pl) | 2011-12-21 | 2023-11-06 | Csl Limited | Schemat dawkowania dla formulacji apolipoproteiny |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| EP2853259A1 (en) * | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| WO2016019333A1 (en) * | 2014-07-31 | 2016-02-04 | Kinemed, Inc. | The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties |
-
2017
- 2017-11-10 SG SG11201903945XA patent/SG11201903945XA/en unknown
- 2017-11-10 CN CN202310189946.6A patent/CN116196395A/zh active Pending
- 2017-11-10 KR KR1020197016627A patent/KR20190084095A/ko not_active Ceased
- 2017-11-10 WO PCT/AU2017/051232 patent/WO2018085890A1/en not_active Ceased
- 2017-11-10 US US16/348,106 patent/US20200038481A1/en not_active Abandoned
- 2017-11-10 KR KR1020247010199A patent/KR20240044543A/ko not_active Withdrawn
- 2017-11-10 EP EP17868674.7A patent/EP3538105A4/en active Pending
- 2017-11-10 BR BR112019007709-0A patent/BR112019007709A2/pt not_active Application Discontinuation
- 2017-11-10 MX MX2019005459A patent/MX2019005459A/es unknown
- 2017-11-10 CN CN201780069271.4A patent/CN109922810A/zh active Pending
- 2017-11-10 CA CA3043110A patent/CA3043110A1/en active Pending
- 2017-11-10 IL IL266428A patent/IL266428B2/en unknown
- 2017-11-10 SG SG10201911714YA patent/SG10201911714YA/en unknown
- 2017-11-10 JP JP2019524144A patent/JP2019533705A/ja active Pending
- 2017-11-10 AU AU2017358402A patent/AU2017358402B2/en active Active
-
2022
- 2022-06-01 JP JP2022089334A patent/JP7464654B2/ja active Active
-
2023
- 2023-08-03 US US18/230,058 patent/US20240207357A1/en active Pending
- 2023-12-15 AU AU2023282314A patent/AU2023282314A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019007709A2 (pt) | 2019-07-09 |
| JP2019533705A (ja) | 2019-11-21 |
| EP3538105A1 (en) | 2019-09-18 |
| KR20190084095A (ko) | 2019-07-15 |
| JP7464654B2 (ja) | 2024-04-09 |
| AU2017358402B2 (en) | 2023-10-05 |
| RU2019117552A (ru) | 2020-12-10 |
| SG10201911714YA (en) | 2020-02-27 |
| US20200038481A1 (en) | 2020-02-06 |
| WO2018085890A1 (en) | 2018-05-17 |
| CN116196395A (zh) | 2023-06-02 |
| IL266428B1 (en) | 2024-08-01 |
| IL266428B2 (en) | 2024-12-01 |
| KR20240044543A (ko) | 2024-04-04 |
| SG11201903945XA (en) | 2019-05-30 |
| US20240207357A1 (en) | 2024-06-27 |
| CA3043110A1 (en) | 2018-05-17 |
| JP2022116254A (ja) | 2022-08-09 |
| IL266428A (en) | 2019-06-30 |
| AU2017358402A1 (en) | 2019-04-18 |
| EP3538105A4 (en) | 2020-05-20 |
| AU2023282314A1 (en) | 2024-01-18 |
| CN109922810A (zh) | 2019-06-21 |
| RU2019117552A3 (https=) | 2021-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019005459A (es) | Tratamiento de infarto de miocardio con lipoproteinas de alta densidad reconstituidas. | |
| MX2019008252A (es) | Agentes de interferencia de acido ribonucleico (iarn) de alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y metodos de uso. | |
| CO2018003678A2 (es) | Composiciones y métodos para inhibir la expresión génica de lpa | |
| CO2020010342A2 (es) | Composiciones de arni de 17 β -hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas | |
| Idialu | The inhuman treatment of widows in African communities | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| EP3402543A4 (en) | CARDIOSPHERE-GENERATING CELLS AND EXOSOMES SECRETED BY SUCH CELLS IN THE TREATMENT OF HEART FAILURES WITH PRESERVED SELECTION | |
| BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
| CR20200108A (es) | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) | |
| AR105470A1 (es) | Métodos para inducir una respuesta inmune | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| BR112015009948A2 (pt) | antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios | |
| MX2021005187A (es) | Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3. | |
| BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
| MX2022004137A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| MX2019002996A (es) | Nanopartículas como sustratos catalíticos para biodetección en tiempo real del desempeño humano y diagnóstico y métodos terapéuticos. | |
| MX2016007658A (es) | Composiciones basadas en metil ciclodextrinas para el tratamiento y/o prevencion de enfermedades aumentando el nivel de colesterol hdl. | |
| MX2019004487A (es) | Metodos y composiciones para el tratamiento de la enfermedad de fabry. | |
| MX2019011188A (es) | Modulacion de la expresion de apolipoproteina c-iii (apociii) en poblaciones con deficiencia de lipoproteina lipasa (lpld). | |
| EP3799871A3 (en) | Pyrazol-3-ones that activate pro-apototic bax | |
| CO2018007165A2 (es) | Terapia génica para tratar hipercolesterolemia familiar | |
| AR120055A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| PE20121700A1 (es) | Composicion que comprende l-carnitina o propionil l-carnitina, troxerutina, diosmina y hesperidina | |
| BR112018008839A2 (pt) | métodos e composições para o tratamento da amiloidose |